Immunopotentiating and Delivery Systems for HCV Vaccines
Development of preventive vaccines against hepatitis C virus (HCV) remains one of the main strategies in achieving global elimination of the disease. The effort is focused on the quest for vaccines capable of inducing protective cross-neutralizing humoral and cellular immune responses, which in turn...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/6/981 |
| _version_ | 1797532737668644864 |
|---|---|
| author | Alexander K. Andrianov Thomas R. Fuerst |
| author_facet | Alexander K. Andrianov Thomas R. Fuerst |
| author_sort | Alexander K. Andrianov |
| collection | DOAJ |
| description | Development of preventive vaccines against hepatitis C virus (HCV) remains one of the main strategies in achieving global elimination of the disease. The effort is focused on the quest for vaccines capable of inducing protective cross-neutralizing humoral and cellular immune responses, which in turn dictate the need for rationally designed cross-genotype vaccine antigens and potent immunoadjuvants systems. This review provides an assessment of the current state of knowledge on immunopotentiating compounds and vaccine delivery systems capable of enhancing HCV antigen-specific immune responses, while focusing on the synergy and interplay of two modalities. Structural, physico-chemical, and biophysical features of these systems are discussed in conjunction with the analysis of their in vivo performance. Extreme genetic diversity of HCV-a well-known hurdle in the development of an HCV vaccine, may also present a challenge in a search for an effective immunoadjuvant, as the effort necessitates systematic and comparative screening of rationally designed antigenic constructs. The progress may be accelerated if the preference is given to well-defined molecular immunoadjuvants with greater formulation flexibility and adaptability, including those capable of spontaneous self-assembly behavior, while maintaining their robust immunopotentiating and delivery capabilities. |
| first_indexed | 2024-03-10T11:03:34Z |
| format | Article |
| id | doaj.art-81d153e0c0a34f2d80a371f56504d7a6 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T11:03:34Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-81d153e0c0a34f2d80a371f56504d7a62023-11-21T21:19:25ZengMDPI AGViruses1999-49152021-05-0113698110.3390/v13060981Immunopotentiating and Delivery Systems for HCV VaccinesAlexander K. Andrianov0Thomas R. Fuerst1Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USAInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USADevelopment of preventive vaccines against hepatitis C virus (HCV) remains one of the main strategies in achieving global elimination of the disease. The effort is focused on the quest for vaccines capable of inducing protective cross-neutralizing humoral and cellular immune responses, which in turn dictate the need for rationally designed cross-genotype vaccine antigens and potent immunoadjuvants systems. This review provides an assessment of the current state of knowledge on immunopotentiating compounds and vaccine delivery systems capable of enhancing HCV antigen-specific immune responses, while focusing on the synergy and interplay of two modalities. Structural, physico-chemical, and biophysical features of these systems are discussed in conjunction with the analysis of their in vivo performance. Extreme genetic diversity of HCV-a well-known hurdle in the development of an HCV vaccine, may also present a challenge in a search for an effective immunoadjuvant, as the effort necessitates systematic and comparative screening of rationally designed antigenic constructs. The progress may be accelerated if the preference is given to well-defined molecular immunoadjuvants with greater formulation flexibility and adaptability, including those capable of spontaneous self-assembly behavior, while maintaining their robust immunopotentiating and delivery capabilities.https://www.mdpi.com/1999-4915/13/6/981immunoadjuvantshepatitis C virus (HCV)vaccinesdelivery systemsimmunopotentiationpharmaceutical formulations |
| spellingShingle | Alexander K. Andrianov Thomas R. Fuerst Immunopotentiating and Delivery Systems for HCV Vaccines Viruses immunoadjuvants hepatitis C virus (HCV) vaccines delivery systems immunopotentiation pharmaceutical formulations |
| title | Immunopotentiating and Delivery Systems for HCV Vaccines |
| title_full | Immunopotentiating and Delivery Systems for HCV Vaccines |
| title_fullStr | Immunopotentiating and Delivery Systems for HCV Vaccines |
| title_full_unstemmed | Immunopotentiating and Delivery Systems for HCV Vaccines |
| title_short | Immunopotentiating and Delivery Systems for HCV Vaccines |
| title_sort | immunopotentiating and delivery systems for hcv vaccines |
| topic | immunoadjuvants hepatitis C virus (HCV) vaccines delivery systems immunopotentiation pharmaceutical formulations |
| url | https://www.mdpi.com/1999-4915/13/6/981 |
| work_keys_str_mv | AT alexanderkandrianov immunopotentiatinganddeliverysystemsforhcvvaccines AT thomasrfuerst immunopotentiatinganddeliverysystemsforhcvvaccines |